ENGN enGene Holdings Inc.
enGene Holdings Inc. (ENGN) is expected to report earnings on September 14, 2026, before the market open. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.9% since its last earnings release on June 15, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About enGene Holdings Inc.
enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.
Sector
Healthcare
Industry
Biotechnology